Differential sensitivity of CD34 epitopes to cleavage by Pasteurella haemolytica glycoprotease: implications for purification of CD34-positive progenitor cells.
Our previous studies have shown that a unique glycoprotease from Pasteurella haemolytica specifically cleaves only proteins containing sialylated O-linked glycans. The hematopoietic progenitor cell antigen, CD34, which is heavily glycosylated with both N- and O-linked glycans, is readily cleaved by this protease. In this study, we demonstrate that the epitopes detected by five of the seven CD34 monoclonal antibodies are removed by the glycoprotease. The differential sensitivity of the CD34 epitopes to cleavage with either neuraminidase and/or glycoprotease establishes three classes of epitopes: 1) (class I) those identified by MY10, B1.3C5, 12.8, and ICH3 that are differentially affected by neuraminidase and removed by the glycoprotease; 2) (class II) the epitope detected by QBEND 10 that is removed only by the glycoprotease; and 3) (class III) those identified by TUK3 and 115.2 that are not removed by either enzyme. Cleavage of the 110-kd CD34 structure by the glycoprotease generates a major cell-bound fragment of about 75 kd, identified by the class III antibodies. We have also used the enzyme to improve the rapid recovery of CD34+ cells selected by immunomagnetic affinity techniques. In a preclinical model, we separated CD34+ KG1 cells with high yield (90%-95%) and high purity (94%-98%) from sham mixtures containing 50% CD34- cells. We also separated CD34+ blast cells from a patient in megakaryoblastic crisis of chronic myelogenous leukemia. In this case, the purity and yield were 93% and 94%, respectively. Enzyme treatment had no detrimental effect on cell viability, and the treated cells showed a normal quantitative expression and distribution of CD34 antigen as assessed with class III antibodies. We conclude that the P. haemolytica glycoprotease has potential to improve the isolation, from human bone marrow, of primitive hematopoietic cells that carry the CD34 antigen.
Sutherland
D R
DR
Oncology Research Laboratory, Toronto Hospital, Ontario, Canada.
Marsh
J C
JC
Davidson
J
J
Baker
M A
MA
Keating
A
A
Mellors
A
A
D015703:Antigens, CD / Q000032:analysis / Q000276:immunology*; D018952:Antigens, CD34; D001752:Blast Crisis / Q000276:immunology; D002469:Cell Separation / Q000379:methods; D000939:Epitopes / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000276:immunology; D008280:Magnetics; D008666:Metalloendopeptidases / Q000494:pharmacology*; D008856:Microscopy, Fluorescence; D009439:Neuraminidase / Q000494:pharmacology; D013234:Stem Cells / Q000166:cytology / Q000276:immunology; D014734:Vibrio cholerae / Q000201:enzymology
D015703:Antigens, CD; D018952:Antigens, CD34; D000939:Epitopes; D009439:Neuraminidase; D008666:Metalloendopeptidases; C070738:O-sialoglycoprotein endopeptidase